Last reviewed · How we verify
Epoetin Alfa 40000 UNT/ML
Epoetin Alfa 40000 UNT/ML is a Erythropoiesis-stimulating agent (ESA) Small molecule drug developed by Australian and New Zealand Intensive Care Research Centre. It is currently in Phase 3 development for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Anemia in critical illness (Phase 3 investigational). Also known as: Eprex, Binocrit, Hemax, Hemax PFS.
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Anemia in critical illness (Phase 3 investigational).
At a glance
| Generic name | Epoetin Alfa 40000 UNT/ML |
|---|---|
| Also known as | Eprex, Binocrit, Hemax, Hemax PFS, Erypo |
| Sponsor | Australian and New Zealand Intensive Care Research Centre |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a glycoprotein that mimics endogenous erythropoietin, promoting erythropoiesis through activation of the erythropoietin receptor on erythroid progenitor and precursor cells in the bone marrow. This leads to increased hemoglobin and hematocrit levels. It is used to treat anemia associated with chronic kidney disease, chemotherapy, and other conditions.
Approved indications
- Anemia of chronic kidney disease
- Chemotherapy-induced anemia
- Anemia in critical illness (Phase 3 investigational)
Common side effects
- Hypertension
- Thrombosis/thromboembolic events
- Headache
- Injection site reactions
- Flu-like symptoms
Key clinical trials
- ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients (PHASE3)
- Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epoetin Alfa 40000 UNT/ML CI brief — competitive landscape report
- Epoetin Alfa 40000 UNT/ML updates RSS · CI watch RSS
- Australian and New Zealand Intensive Care Research Centre portfolio CI
Frequently asked questions about Epoetin Alfa 40000 UNT/ML
What is Epoetin Alfa 40000 UNT/ML?
How does Epoetin Alfa 40000 UNT/ML work?
What is Epoetin Alfa 40000 UNT/ML used for?
Who makes Epoetin Alfa 40000 UNT/ML?
Is Epoetin Alfa 40000 UNT/ML also known as anything else?
What drug class is Epoetin Alfa 40000 UNT/ML in?
What development phase is Epoetin Alfa 40000 UNT/ML in?
What are the side effects of Epoetin Alfa 40000 UNT/ML?
What does Epoetin Alfa 40000 UNT/ML target?
Related
- Drug class: All Erythropoiesis-stimulating agent (ESA) drugs
- Target: All drugs targeting Erythropoietin receptor (EPOR)
- Manufacturer: Australian and New Zealand Intensive Care Research Centre — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Anemia of chronic kidney disease
- Indication: Drugs for Chemotherapy-induced anemia
- Indication: Drugs for Anemia in critical illness (Phase 3 investigational)
- Also known as: Eprex, Binocrit, Hemax, Hemax PFS, Erypo
- Compare: Epoetin Alfa 40000 UNT/ML vs similar drugs
- Pricing: Epoetin Alfa 40000 UNT/ML cost, discount & access